In DLBCL, oncogenic miR-155 inhibited Smad5 expression and rendered cells resistant to the growth inhibitory effects of both TGF-β1 and BMPs, via a defective p21 induction and decreased formation of the RB/E2F1 complex [177,178]. The gene discussed is TGFB1; the disease is diffuse large B-cell lymphoma.